Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Shares Outstanding (Weighted Average): 2013-2025

Historic Shares Outstanding (Weighted Average) for Theravance Biopharma (TBPH) over the last 13 years, with Sep 2025 value amounting to $50.4 million.

  • Theravance Biopharma's Shares Outstanding (Weighted Average) rose 2.41% to $50.4 million in Q3 2025 from the same period last year, while for Jun 2025 it was $50.0 million, marking a year-over-year increase of 2.21%. This contributed to the annual value of $49.2 million for FY2024, which is 2.10% up from last year.
  • Theravance Biopharma's Shares Outstanding (Weighted Average) amounted to $50.4 million in Q3 2025, which was up 0.72% from $50.0 million recorded in Q2 2025.
  • In the past 5 years, Theravance Biopharma's Shares Outstanding (Weighted Average) ranged from a high of $76.4 million in Q2 2022 and a low of $48.2 million during Q4 2023.
  • For the 3-year period, Theravance Biopharma's Shares Outstanding (Weighted Average) averaged around $51.3 million, with its median value being $49.5 million (2025).
  • Its Shares Outstanding (Weighted Average) has fluctuated over the past 5 years, first grew by 18.32% in 2022, then tumbled by 34.84% in 2023.
  • Theravance Biopharma's Shares Outstanding (Weighted Average) (Quarterly) stood at $73.7 million in 2021, then fell by 14.70% to $62.9 million in 2022, then declined by 23.38% to $48.2 million in 2023, then climbed by 2.10% to $49.2 million in 2024, then climbed by 2.41% to $50.4 million in 2025.
  • Its last three reported values are $50.4 million in Q3 2025, $50.0 million for Q2 2025, and $49.5 million during Q1 2025.